The present study was designed to determine whether or not the administration of MGN-3 (also known as Lentin Plus 1000) could have its apothanasia effect and improve the QOL for 205 progressive and partially metastasized cancer patients in late III-IV stages after surgery. MGN-3 is a rice bran arabinoxylan derivative and known to have immunomodulation activity.

The participants in this clinical study are hospitalized patients in our clinic treated with complementary alternative medicines (we call it "Non-Conventional Therapy") and anticancer medicines with fewer side effects. The 205 patients hospitalized for 6 months were grouped into two groups, viz, 109 patients (control group) treated with our standard complementary alternative medicines, and 96 patients who were further given MGN-3 (MGN-3 group) for one year and a half. 

All the patients were measured for natural killer activity as an indication for the variation of immunoparameters. Simultaneously, the QOL of the patients was also checked. The NK cell activities of the patients after surgery were low on average; however, by the administration of MGN-3, NK activity was observed to increase and the apothanasia ratio also increased; the higher the patient NK activity is, the higher the apothanasia ratio was observed to rise. The above findings indicate that NK activity can be used as a pathological index of progressive cancers. QOL improvement was also observed with the administration of MGN-3.